Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Girard, P. Duquette, W. Sibley (1993)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.Neurology
B. Khatri, M. Mcquillen, R. Hoffmann, H. Weiner, S. Hauser, D. Dawson, D. Hafler, G. Mackin, E. Orav, R. Currier, A. Haerer, J. Files, FrancisS. Morrison (1991)
Cyclophosphamide and plasma exchange in multiple sclerosisThe Lancet, 337
R Kinkel, R. Rudick, R. Ransohoff (1997)
Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma.Journal of Neurology, Neurosurgery & Psychiatry, 62
D. Paty, D. Li (1993)
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 43
DW Paty, DK Li (1993)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial., 43
L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, J. Alam, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weinstock-Guttman, R. Whitham (1996)
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 39
D. Goodkin, D. Cookfair, K. Wende, D. Bourdette, P. Pullicino, B. Scherokman, R. Whitham (1992)
Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS)Neurology, 42
J. Simon, L. Jacobs, M. Campion, K. Wende, N. Simonian, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Alam, J. Fischer, D. Goodkin, C. Granger, M. Lajaunie, A. Martens-Davidson, M. Meyer, J. Sheeder, K. Choi, A. Scherzinger, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, Roger Scd, P. Pullicino, B. Scherokman, B. Weinstock-Guttman, R. Whitham (1998)
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosisAnnals of Neurology, 43
Lawrence Jacobs, Kenneth Johnson (1994)
A brief history of the use of interferons as treatment of multiple sclerosis.Archives of neurology, 51 12
B. Weinshenker, B. Bass, G. Rice, J. Noseworthy, W. Carriere, J. Baskerville, G. Ebers (1989)
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.Brain : a journal of neurology, 112 ( Pt 6)
R. Rudick, D. Goodkin, L. Jacobs, D. Cookfair, R. Herndon, J. Richert, A. Salazar, J. Fischer, C. Granger, J. Simon, J. Alam, N. Simonian, M. Campion, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weistock-Guttman, R. Whitham (1997)
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosisNeurology, 49
(1995)
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial., 45
CONTROVERSIES IN NEUROLOGY SECTION EDITOR: VLADIMIR HACHINSKI, MD, FRCPC, DSCMED Do They Prevent the Progression of the Disease? George Rice, MD, FRCPC; George Ebers, MD, FRCPC HERE IS little doubt score on the Kurtzke Expanded Dis- duction by presenting the attack fre- that treatment of ability Status Scale) compared with quency in patients followed up for multiple sclerosis 28% of patients treated with pla- 102 weeks. This percentage de- (MS) with type 1 in- cebo. This difference did not reach rived from a post hoc subgroup T terferons reduces the statistical significance (P = .16). analysis that was not corrected for frequency of clinical exacerba- Several reasons were offered to the statistically challenging effect of tions. This observation has been cor- explain this shortfall in disability multiple comparison. Further- roborated repeatedly. Treatment of outcome. First, the study was nei- more, much of the effect can be at- 124 patients with recombinant in- ther designed nor powered statisti- tributed to an unusually high fre- terferon beta-1b (IFN-b-1b) re- cally to identify a moderate effect on quency of attacks that occurred in duced the frequency of attacks by disease progression. This would have small numbers of patients in the pla- 33.8%.
JAMA Neurology – American Medical Association
Published: Dec 1, 1998
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.